Expand TGTX Menu
TGTX MENU

TGTX Latest Press Releases

-- May 1, 2024 --

TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results Globe Newswire 7:00 AM

-- April 30, 2024 --

TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update Globe Newswire 4:55 PM

-- April 18, 2024 --

TG Therapeutics Announces Additional Data Presentations for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting Globe Newswire 7:30 AM
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis Globe Newswire 7:00 AM

-- April 15, 2024 --

TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting Globe Newswire 7:30 AM

-- March 27, 2024 --

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update Business Wire 6:45 AM

-- March 8, 2024 --

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting Globe Newswire 7:30 AM

-- March 1, 2024 --

TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum Globe Newswire 7:30 AM

-- February 28, 2024 --

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results Globe Newswire 7:00 AM

-- February 27, 2024 --

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI (ublituximab-xiiy) Globe Newswire 7:30 AM

-- February 26, 2024 --

TG Therapeutics Announces European Launch of BRIUMVI (ublituximab-xiiy) Globe Newswire 7:00 AM

-- February 23, 2024 --

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update Globe Newswire 7:30 AM

-- February 20, 2024 --

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum Globe Newswire 7:30 AM

-- February 12, 2024 --

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases Business Wire 7:00 AM

-- January 10, 2024 --

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones Globe Newswire 7:00 AM

-- January 9, 2024 --

Biotech Bid Up Before Opening Bell Yolowire 9:59 AM
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases Business Wire 7:00 AM
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases Globe Newswire 7:00 AM

-- January 5, 2024 --

TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference Globe Newswire 7:30 AM